Medical and Scientific Experts and Educators Bruce E. Miller, PhD, Chief Scientific Officer Timothy Aksamit, MD, Bronchiectasis and NTM 360 Medical Director Courtney Crim, MD, COPD360 Medical Director Alan Hamilton, PhD, Senior Director of Research Nicholas Locantore, PhD, Senior Director of Digital Data Collection and Integration David M. Mannino III, MD, FCCP, FERS, Medical Director and Co-Founder Byron Thomashow, MD, Co-Founder and Chief Medical Officer Delia P. Oliver, BSEd, MSEd, VP of Bronchiectasis and NTM 360 Educators Amanda Atkinson, MSN, RN, Manager of Patient and Professional Education Michael W. Hess, MPH, RRT, RPFT, Senior Director of Public Outreach and Education Christina Hunt, BS, RRT-NPS, Director of Bronchiectasis and NTM Research and Education Kristen Szymonik, BS, RRT, AE-C, Assistant Director of Education Bruce E. Miller, PhD, Chief Scientific Officer Bruce Miller, PhD, is the Chief Scientific Officer at the COPD Foundation. He is also the scientific lead for COPD360Net, the Foundation's Digital Health and Therapeutics Development Accelerator and represents the Foundation on committees that oversee the COPDGene and SPIROMICS studies. Prior to joining the Foundation, he held senior scientific roles at several pharmaceutical firms, including Sterling Winthrop Pharmaceuticals, Rhone-Poulenc Rorer, Johnson & Johnson, and GlaxoSmithKline (GSK). During his 15 years at GSK, Dr. Miller led several COPD drug development projects and was involved in numerous public-private collaborations that significantly contributed to disease understanding in COPD. While at GSK, Dr. Miller served as industry co-chair for the COPD Biomarker Qualification Consortium (CBQC) Fibrinogen Working Group, an effort that resulted in the first regulatory qualification with the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a biomarker as a drug development tool to support COPD clinical trials. He has authored or co-authored approximately 200 peer-reviewed publications in the areas of respiratory research and inflammation/immunology. Education: Degrees BS —Biology/Chemistry - State University of New York at Albany (1981) PhD —Pharmacology and Toxicology - The University of North Carolina at Chapel Hill (1988) Fellowships Post-doctoral fellowship, Pharmacology - Glaxo, Inc. (1989-1991) Videos: https://youtu.be/mn9YNNJYZLw Select Publications: Prevalence and Characteristics of Individuals with Preserved Ratio Impaired Spirometry (PRISm) and/or Impaired Lung Function in Japan: The OCEAN Study. Int J Chron Obstruct Pulmonary (2021). 16:2665-2675. Utility of Self-Administered Questionnaires for Identifying Individuals at Risk of COPD in Japan: The OCEAN (Okinawa COPD case finding assessment) Study. Int J Chron Obstruct Pulmon (2021) 16:1771-1782. Inflammatory Endotype-Associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. Am J Respir Crit Care Med (2021) 203:1488-1502. Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness. Int J Chron Obstruct Pulmon (2021). 16:41-51. Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. Eur Respir J. (2021) :2001339. Close Timothy Aksamit, MD, Bronchiectasis and NTM 360 Medical Director Timothy Aksamit, MD, is a consultant and Associate Professor of Medicine in the Pulmonary Disease and Critical Care Medicine Division at Mayo Clinic Rochester, MN, and is the Medical Director of the Mayo Mycobacterial and Bronchiectasis Clinic. He was a founding member and previous chair of the United States Bronchiectasis and NTM Research Registry for six years and currently supports the Foundation's bronchiectasis and NTM strategy as Medical Director of the Bronchiectasis and NTM 360 initiative. He is co-chair of World Bronchiectasis Day. He has additionally served as Director for the Medical ICU at St. Mary's Clinic with the Mayo Clinic for six years. Dr. Aksamit has co-authored an international position statement on nontuberculous mycobacteria by the American Thoracic Society and Infectious Disease Society of America, and he is a founding member of an international NTM consortium (NTM-NET). He helped develop and implement a tuberculosis clinic collaboration between the Mayo Clinic and the Olmsted County Public Health Department and currently serves as its director. Dr. Aksamit has previously been involved with the CDC-sponsored Heartland National TB Center as a faculty member, advisory committee member, and medical consultant; and previously served as a member and subsequent chair of the State of Minnesota Tuberculosis Advisory Committee. He is the medical director of Spiritual Care Services at St. Mary's Hospital Campus Mayo Clinic Rochester, MN. Education: Degrees BS, Chemistry - The University of Illinois at Urbana-Champaign (1981) MD - Northwestern University Feinberg School of Medicine (1985) Residency Internal Medicine and Chief Resident - University of Iowa Hospitals and Clinics (1985-1988) Fellowship oyal Postgraduate Medical School - Hammersmith Hospital (1990) Pulmonary Disease and Critical Care Medicine - University of Iowa Hospitals and Clinics (1988-1991) Videos: https://www.youtube.com/watch?v=mvUZdZkm8t4 https://youtu.be/aXbOg32_DUw Select Publications: Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. (2018). DOI: 10.1164/rccm.201807-1318OC Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J (2017). DOI: 10.1183/13993003.00051-2017 Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respir Med. (2022). DOI: 10.1016/S2213-2600(21)00277-0. Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry. Chest. (2017). May;151(5):982-992. DOI: 10.1016/j.chest.2016.10.055 An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respirit Crit Care Med (2007). DOI: 10.1164/rccm.200604-571ST. Close Courtney Crim, MD, COPD360 Medical Director Courtney Crim, MD, is the COPD360 Medical Director for the Foundation. He supports COPD360Net, the Foundation's initiative to facilitate, review, and expedite clinical trials for new therapies and digital health tools while also providing support to the Foundation's COPD360 Coach program. Dr. Crim is currently a Clinical Associate Professor of Medicine in Pulmonary and Critical Care Medicine at the University of North Carolina-Chapel Hill. Most recently, he served as Group Director in Clinical Development in Respiratory Clinical Sciences at GlaxoSmithKline and was a member of the U.S. Food and Drug Administration Pulmonary and Allergy Drug Advisory Committee early in his career. Dr. Crim has over 20 years of experience in pharmaceutical clinical development, and medical affairs governance that led to the development of novel chemical entities from Phase II through IV clinical trials and post-marketing regulatory requirements. Education: Degrees BS - Chemistry, University of Michigan (1973) MD - University of Michigan Medical School (1977) Residencies and Internships Internship, Internal Medicine - Baylor College of Medicine (1978) Residency, Internal Medicine - Henry Ford Hospital (1981) Fellowships Pulmonary Disease and Critical Care Medicine - University of Michigan (1984) Select Publications Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials. International Journal of Chronic Obstructive Pulmonary Disease (2021). DOI: https://doi.org/10.2147/COPD.S302864 Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness.International Journal of Chronic Obstructive Pulmonary Disease (2021). DOI: https://doi.org/10.2147/COPD.S279645 The Summit Score Stratifies Mortality and Morbidity in Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease (2020). DOI: https://doi.org/10.2147/COPD.S254437 FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. International Journal of Chronic Obstructive Pulmonary Disease (2020). DOI: https://doi.org/10.2147/COPD.S242809 Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease (2019). DOI: https://doi.org/10.2147/COPD.S190603 Close Alan Hamilton, PhD, Senior Director of Research Alan Hamilton, PhD, joined the Foundation in early 2022 as the Senior Director of Research. As the program lead for the Foundation's Patient Inspired Validation of Outcome Tools (PIVOT) initiative, Dr. Hamilton has a major focus on activities related to the development and evaluation of pharmacological and non-pharmacological interventions for COPD, Bronchiectasis, NTM lung disease, and other chronic lung diseases. In addition to his primary role as PIVOT lead, he also provides subject matter expertise to the Foundation on topics related to pulmonary rehabilitation, including exercise training and testing, self-management, and behavior change. Throughout his decades-long academic and industry career, Dr. Hamilton has shown a passion for developing and evaluating interventions that target the alleviation of breathlessness and associated activity limitations in COPD. Between 2013 and 2021, he represented Boehringer Ingelheim in the COPD Biomarker Qualification Consortium (CBQC). He served as industry co-chair for the Constant Work Rate Exercise Working Group, and recently served as industry co-chair for the CBQC Steering Committee. A highlight of Dr. Hamilton's career was his role as a global clinical program lead for a once-daily long-acting muscarinic antagonist/beta-agonist combination. He recently joined the planning committee for the American Thoracic Society Pulmonary Rehabilitation Assembly. Education: Degrees BS— Chemistry - University of Nottingham (1986) MS— Sport Science - Loughborough University (1987) PhD, Physiology and Pharmacology - McMaster University (1995) Postdoctoral Fellowship Pharmacology - McMaster University (1995 - 1997) Videos: https://youtu.be/oGbytnCFBpE Select Publications: A Conceptual Framework for Use of Increased Endurance Time During Constant Work Rate Cycle Ergometry as a Patient-Focused Meaningful Outcome in COPD Clinical Trials. Chronic Obstructive Pulmonary Disease (2022). 9(2):252-265. Objectively Measured Physical Activity as a COPD Clinical Trial. Chest (2021); 160(6):2080-2100. Mechanisms associated with increased physical activity in patients undergoing self-management behaviour modification in the randomised PHYSACTO trial. ERJ Open Res. (2021). 7(1):00533-2020. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur Respir J (2021). DOI: 10.1183/13993003.02049-2018 Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2018). DOI: 10.1164/rccm.201706-1288OC Close Nicholas Locantore, PhD, Senior Director of Digital Data Collection and Integration Nicholas Locantore, PhD, is the Senior Statistical Director for the Foundation. He has more than 20 years of experience in clinical research, statistical consulting, and digital data integration. At the Foundation, Locantore is primarily engaged with the Patient Powered Research Network (PPRN). Education: BA— Mathematics - Trenton State College PhD— Statistics - University of North Carolina at Chapel Hill Select Publications: Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine. (2010) DOI: 10.1056/NEJMoa0909883. Real-World use of rescue inhaler sensors, electronic symptom questionnaires and physical activity monitors in COPD. BMJ Open Respiratory Research (2019). DOI: 10.1136/bmjresp-2018-000350. COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development. Respiratory Medicine. (2020). DOI: 10.1016/j.rmed.2020.106175 Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. European Respiratory Journal. (2020). DOI: 10.1183/13993003.01339-2020. Blood eosinophil counts, exacerbations and response to the addition of inhaled fluticasone furoate to vilanterol in patients with COPD. The Lancet Respiratory Medicine (2015) DOI: 10.1016/S2213-2600(15)00106-X. Close David M. Mannino III, MD, FCCP, FERS, Medical Director and Co-Founder David Mannino, MD, was part of the original team that launched the COPD Foundation and has served the Foundation in multiple roles, including Chair of the Medical and Scientific Advisory Committee, Chief Scientific Officer, and Associate Editor of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. He formerly held a position at the Centers for Disease Control and Prevention. where he helped launch the National Asthma Program and worked on the epidemiology of COPD. In 2004, Dr. Mannino retired from the U.S. Public Health Service and started his academic career at the University of Kentucky in Lexington, where he was part of the international Burden of Lung Disease (BOLD) team, with the only U.S. site. Following a three-year stint as a U.S. Medical Expert at GlaxoSmithKline where he focused on COPD, he returned to the COPD Foundation as a Medical Director in November 2020. Education: Degrees BS - The Pennsylvania State University (1979) MD - Jefferson Medical College at Thomas Jefferson University (1981) Residency Internal Medicine - Lankenau Hospital (1984) Fellowship Pulmonary - West Virginia University (1991) Videos: https://youtu.be/WCRq2JUaMac https://youtu.be/gQK_9ZzIqYA Selected Publications: A rapidly changing understanding of COPD: World COPD Day from the COPD Foundation. Am J Physiol Lung Cell Mol Physiol. (2021) PMID: 34612086. Prevalence and Population Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study. Am J Respir Crit Care Med. (2020). PMCID: PMC8456536. Asthma-COPD Overlap and Chronic Airflow Obstruction: Definitions, Management, and Unanswered Questions. J Allergy Clin Immunol Pract. (2020) PMID: 31740296. Fifty Years of Progress in the Epidemiology of Chronic Obstructive Pulmonary Disease: A Review of National Heart, Lung, and Blood Institute-Sponsored Studies. Chronic Obstr Pulm Dis. (2019). PMCID: PMC7006703. Asthma, COPD and their overlap: coexistence or something more? Eur Respir J. (2021). PMID: 34824127. Close Byron Thomashow, MD, Co-Founder and Chief Medical Officer Dr. Byron Thomashow helped found the COPD Foundation in 2004 and served as Chairman of the Board of Directors for ten years. As of July 2018, he took on the role of Chief Medical Officer of the Foundation. He has served as co-chair for the NY State COPD Coalition, co-chaired the New York State COPD Summit in 2010, the COPD7 USA 2011, COPD8 USA 2013, COPD 9USA 2015, COPD10 USA 2017, and the COPD Readmission Summits in October 2013 and March 2015. Dr. Thomashow is currently a Professor Emeritus at Columbia University Vagelos College of Physicians and Surgeons and a Special Lecturer at New York-Presbyterian/Columbia University Irving Medical Center. He spent many years as a Professor of Medicine and an Attending Physician at that institution. He was the medical co-director of the Jo-Ann LeBuhn Center for Chest Disease at Columbia University Irving Medical Center and medical director of the New York-Presbyterian Lung Volume Reduction program. He chaired the Respiratory Disease Council of the New York-Presbyterian Healthcare Network for many years and co-chaired the New York-Presbyterian smoking cessation initiative leading to campus going smoke-free. The Byron M. Thomashow Professorship of Medicine at Columbia University Vagelos College of Physicians and Surgeons was established in his honor in 2006. He was awarded the 2013 American Thoracic Society Public Advisory Roundtable Excellence Award. In 2016, he received the Columbia University Leonard Tow Humanism in Medicine Award sponsored by the Arnold P. Gold Foundation. In 2017, he received the Albert Nelson Marquis Lifetime Achievement Award and in 2018 received the JW Walsh Visionary Award from the COPD Foundation. He received the Milstein Service Award from Columbia University and New York-Presbyterian Hospital in 2022. He was a member of the steering committee and the co-primary investigator at the Columbia site for the National Emphysema Treatment Trial and has been actively involved in multiple national clinical research projects including the development and validation of the CAPTURE tool (COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk). Education: Degrees BA - Columbia College (1970) MD - Columbia University, College of Physicians and Surgeons (1974) Residency Medical Internship - Roosevelt Hospital (1975) Medical Resident - Roosevelt Hospital (1978) Fellowships Chief Medical Resident and Pulmonary Fellow - Roosevelt Hospital (1978) Senior Pulmonary Fellow - Roosevelt Hospital (1979) Close Delia P. Oliver, BSEd, MSEd, VP of Bronchiectasis and NTM 360 Delia P. Oliver is the VP for Bronchiectasis and NTM 360 at the COPD Foundation. She has worked with the Foundation since 2009 and joined the team full-time in 2011. In her role at the Foundation, she is responsible for leading the Bronchiectasis and NTM 360 team and overseeing its programs including the Bronchiectasis and NTM Research Registry, BronchandNTM360social, and World Bronchiectasis Day. Delia has extensive experience managing patient registries and research consortia, and serves a critical role in connecting patients, health care providers, researchers, and industry partners to work collaboratively to advance research in the fields of COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease. Education: BSEd, Human and Social Development, University of Miami (2011) MSEd, Community and Social Change, University of Miami (2013) Select Publications, Articles, and Special Projects A list of publications generated from the programs of Bronchiectasis and NTM 360 can be found here. Close Amanda Atkinson, MSN, RN, Manager of Patient and Professional Education Amanda Atkinson, MSN, RN is the Manager of Patient and Professional Education for the COPD Foundation. In this role she develops educational resources for health care professionals, patients, and caregivers, improving awareness of and accessibility to the latest evidence-based research, innovation, and information. Atkinson comes from a diverse clinical background where she provided care to patients with a variety of health conditions. She has held educational roles over the course of her career in both the health care and corporate sectors, including serving as adjunct faculty for the community and technical college system. She also co-authored a curriculum for use in non-profit recovery homes. Atkinson has a passion for empowering patients, caregivers, and providers by creating educational tools to improve quality of care, enabling patients to live their best lives. Education: MS, Nursing Education, Northern Kentucky University (2021) AS— Nursing, Western Kentucky University (2018) BA — Business, Mid-Continent University (2005) Select Publications, Articles, and Special Projects Need Tips for Your Mental Health Toolkit This Holiday? Genetic COPD 101 Do Your Asthma Symptoms Get Worse With Stress? Don't Worry, Breathe Easy Intimacy and Living Well With COPD Living Well With Multiple Health Conditions Close Michael W. Hess, MPH, RRT, RPFT, Senior Director of Public Outreach and Education Michael W. Hess, MPH, RRT, RPFT, is the Senior Director of Public Outreach and Education. He leads the Foundation's project, which facilitates oxygen equipment innovation and research, promotes policy improvements surrounding oxygen reimbursement, and enhances clinician education on the appropriate use of this critical therapy. Before joining the Foundation, Hess served as the Chronic Lung Disease Coordinator at WMed Health in Kalamazoo, Michigan. He provided patient education, diagnostic testing, care coordination, and other respiratory care services as part of a primary care clinic, while also designing and implementing community outreach programs to enhance respiratory health. In 2019, he was selected as Ambulatory and Post-Acute Care Specialty Practitioner of the Year by the American Association for Respiratory Care. Education: AAS, Respiratory Care Therapist/Therapy - Kalamazoo Valley Community College (2006) BS, Interdisciplinary Health Services - Western Michigan University (2015) MPH, Public Health Education and Promotion - Western Michigan University (2019) Videos: https://www.copdfoundation.org/Research/Research-Projects-and-Consortia/Oxygen360.aspx https://www.youtube.com/watch?v=heOWhBOkQFA https://www.youtube.com/watch?v=golclEqQdiE&t=241s https://www.youtube.com/watch?v=Pn_ejFeNnvQ https://www.youtube.com/watch?v=O8eFFn7VgZA Select Publications, Articles, and Special Projects: Supplemental Oxygen Management by Respiratory Therapists Is a Blueprint for Lowering the Burden of COPD on the Health Care System. Respiratory Care. (2022) DOI: 10.4187/respcare.10418 Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease. (2022) DOI: 10.2147/copd.s319511 The Role of the Pharmacist in Inhaler Selection and Education in Chronic Obstructive Pulmonary Disease. Journal of Pharmacy Technology. (2021) DOI: 10.1177/8755122520937649 The 2017 Global Initiative for Chronic Obstructive Lung Disease Report and Practice Implications for the Respiratory Therapist. Respiratory Care. (2017) DOI: 10.4187/respcare.05402 Back to the future: past, present and future is COPD360. Chronic Obstr Pulm Dis. (2016) DOI: http://doi.org/10.15326/jcopdf.3.1.2015.0173 Close Christina Hunt, BS, RRT-NPS, Director of Bronchiectasis and NTM Research and Education Christina Hunt, RRT-NPS, is the Director of Bronchiectasis and NTM Research and Education for the Foundation. In this role, she creates patient educational resources and assists with research projects that are part of Bronchiectasis and NTM360, a program started by the Foundation several years ago because of the significant overlap between COPD and these two chronic lung diseases. Hunt is a registered respiratory therapist and has worked in respiratory care for more than 20 years including in adult, pediatric, and neonatal intensive care units, critical care transport teams, and most recently, pulmonary rehabilitation. She has worked as a respiratory department clinical educator at Bon Secours St. Mary’s Hospital and as both adjunct faculty and a clinical instructor for respiratory care students at J. Sargeant Reynolds Community College. In 2018, Hunt developed a successful blog, BreatheLiveFit.com, to help people with chronic lung conditions live happier, healthier lives. She also serves on the board of directors for Breath Matters Support Group of Virginia. Education: BS, Human Food, Nutrition, and Exercise - Virginia Tech RRT, Registered Respiratory Therapist Videos: https://www.youtube.com/watch?v=plJYuH7F9kE https://www.youtube.com/watch?v=F09vXG7wckQ https://www.youtube.com/watch?v=mvUZdZkm8t4 Publications, Articles, and Special Projects: World Bronchiectasis Day campaign Courageous conversation: Talking to your patients about advance directives Beyond the Lungs: How COPD affects the body Nothing But The Truth: Myths About Pulmonary Rehab or Exercise Close Kristen Szymonik, BS, RRT, AE-C, Assistant Director of Education Kristen Szymonik, BS, RRT, AE-C, is the Assistant Director of Education for the COPD Foundation. She develops and edits educational materials for patients and community outreach projects. Szymonik is a registered respiratory therapist, certified asthma educator, and medical writer. Prior to joining the Foundation, she designed and implemented one of the first comprehensive asthma education programs in the Chicago suburbs, providing inpatient, outpatient, and community-based education for patients and families. She served a term on the National Asthma Educator Certification Board, where she collaborated with medical professionals from all disciplines and backgrounds. As a medical writer, Szymonik developed numerous continuing education classes for health care providers, wrote study guides for national-level board exams, and presented lectures for healthcare providers on the management of asthma and allergies. She also serves as an author and faculty member on a web-based nursing education forum. Education: BS - Respiratory Care, National-Louis University (2001) Videos: https://www.youtube.com/watch?v=MOevBZ2Vemo https://www.youtube.com/watch?v=WowrkfXoSpI&t=14s Select Publications, Articles, and Special Projects: Educational Materials CIRCLES Project Provider Learning Opportunities - Reviewer Close
Join Us on COPD360social Join the Conversation Become a Member > Already a Member? Sign In to Participate >
This page was reviewed on October 9, 2023 by the COPD Foundation Content Review and Evaluation Committee.